Market research
IPH.PA Innate Pharma S.A
PA EUR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 145M
- P/E ratio
- Not available
- Analyst target
- 5.9
- Dividend yield
- Not available
- Beta
- 1.19
Profile
Instrument facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- FR0010331421
- Market cap
- 145M
- P/E ratio
- Not available
- Analyst target
- 5.9
- Dividend yield
- Not available
- Beta
- 1.19
About
About Innate Pharma S.A
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.
Research context
Innate Pharma S.A appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the IPH.PA discussion.
5 years, 6 months ago
Innate Pharma S.A is currently in a long term downtrend where the price is trading 21.5% below its 200 day moving average.
From a valuation standpoint, the stock is 98.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.2.
Innate Pharma S.A's total revenue sank by 0.0% to $13M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $-17M since the same quarter in the previous year.
Finally, its free cash flow grew by 123.2% to $3M since the same quarter in the previous year.
Based on the above factors, Innate Pharma S.A gets an overall score of 2/5.